We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.
- Authors
Dickson, M A; Okuno, S H; Keohan, M L; Maki, R G; D'Adamo, D R; Akhurst, T J; Antonescu, C R; Schwartz, G K
- Abstract
HSP90 inhibition leads to proteosomal degradation of activated KIT and has in vitro activity against gastrointestinal stromal tumors (GIST). BIIB021 is an oral non-ansamycin HSP90 inhibitor. We carried out a phase II study of BIIB021 in patients with GIST refractory to imatinib and sunitinib.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Vol 24, Issue 1, p252
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mds275